Premium
Adriamycin in the treatment of childhood solid tumors. A southwest oncology group study
Author(s) -
Ragab Abdelsalam H.,
Sutow Wataru W.,
Komp Diane M.,
Starling Kenneth A.,
Lyon George M.,
George Stephen
Publication year - 1975
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197511)36:5<1567::aid-cncr2820360505>3.0.co;2-i
Subject(s) - medicine , leukopenia , vomiting , nausea , rhabdomyosarcoma , stomatitis , regimen , chemotherapy , lymphoma , vincristine , oncology , gastroenterology , surgery , cyclophosphamide , sarcoma , pathology
Ninety‐eight children with solid tumors resistant to conventional chemotherapy received adriamycin 90 mg/m 2 , either as a single intravenous injection or in 6 divided doses administered every 6 hours. Of the 88 evaluable children, 6 (7%) achieved a complete response and 26 (29%) achieved a partial response. Tumors which demonstrated significant response rates were: neuroblastoma (9/18), Wilms' tumor (7/13), rhabdomyosarcoma (4/11), and lymphoma (4/8). The toxicities observed with this regimen included: alopecia, leukopenia, thrombocytopenia, nausea, vomiting, stomatitis, febrile episodes, and ST‐segment changes.